Joza Jacqueline, Gustavo Bravosi da Rosa Luiz, Alturki Ahmed, Anglesio Valeria, Sanchez-Somonte Paula, Poletaev Vladimir, Bernier Martin, Verma Atul, Essebag Vidal
McGill University Health Center, Montreal, Quebec, Canada.
Hôpital Sacré-Cœur de Montréal, Montréal, Québec, Canada.
Int J Cardiol Heart Vasc. 2024 Feb 13;51:101360. doi: 10.1016/j.ijcha.2024.101360. eCollection 2024 Apr.
Cardioneuroablation (CNA) is an ablation technique that targets epicardial ganglionic plexi to reduce syncope burden and avoid pacemaker implantation in patients with cardioinhibitory vasovagal syncope (VVS). This study aims to demonstrate feasibility and safety of CNA in high-risk refractory VVS patients using continuous monitoring with an implantable loop recorder (ILR).
Data was collected prospectively for patients undergoing CNA. Patients were required to have recurrent syncope with documented asystole, refractory to conservative measures. Ganglionic plexi (GPs) were identified by fragmented signals and high frequency stimulation (HFS). Ablation was performed until loss of positive response to HFS, Wenckebach cycle shortening was achieved, or an increase in sinus rate of > 20 bpm. Follow-up was performed through remote and clinic follow-up of their ILRs.
Between December 2020 and July 2023 six patients (mean age 29 ± 3, 67 % female)underwent CNA. The baseline heart rate and Wenckebach cycle length was 63.2 ± 15 bpm and 582 ms before and 91 ± 5 bpm and 358 ms after ablation respectively. During a median follow-up of 13.4 months, 3/5 patients had no further syncopal episodes, 1 had a recurrence, underwent repeat CNA with no further episodes at 1 year, and 1 had 5 syncopal events, which was a dramatic reduction from nearly daily episodes pre-CNA. There were no procedure related complications.
A dramatic reduction in documented pauses and syncope burden was noted post CNA. Appropriate patient selection with rigorous objective follow-up in an experienced center is necessary. Larger studies are required to confirm these findings.
心脏神经消融术(CNA)是一种针对心外膜神经节丛的消融技术,旨在减轻心脏抑制性血管迷走性晕厥(VVS)患者的晕厥负担并避免植入起搏器。本研究旨在通过使用植入式循环记录仪(ILR)进行连续监测,证明CNA在高危难治性VVS患者中的可行性和安全性。
前瞻性收集接受CNA治疗患者的数据。患者需有记录到心脏停搏的复发性晕厥,且对保守治疗无效。通过碎裂信号和高频刺激(HFS)识别神经节丛(GPs)。进行消融直至对HFS的阳性反应消失、文氏周期缩短或窦性心率增加>20次/分。通过对其ILR进行远程和门诊随访。
2020年12月至2023年7月期间,6例患者(平均年龄29±3岁,67%为女性)接受了CNA。消融前基线心率和文氏周期长度分别为63.2±15次/分和582毫秒,消融后分别为91±5次/分和358毫秒。在中位随访13.4个月期间,5例患者中有3例未再发生晕厥,1例复发,接受了重复CNA,1年后未再发作,1例有5次晕厥事件,与CNA前几乎每日发作相比有显著减少。无手术相关并发症。
CNA后记录到的停搏和晕厥负担显著降低。在经验丰富的中心进行适当的患者选择并进行严格的客观随访是必要的。需要更大规模的研究来证实这些发现。